Harmony Biosciences Reports First Quarter 2022 Financial Results and Business UpdatesGlobeNewsWire • 05/03/22
HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIAPRNewsWire • 04/27/22
HARMONY BIOSCIENCES TO PARTICIPATE IN 21st ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCEPRNewsWire • 04/04/22
HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FOURTH CONSECUTIVE YEARPRNewsWire • 03/31/22
HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAMPRNewsWire • 03/17/22
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 02/28/22
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business UpdatesGlobeNewsWire • 02/28/22
Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial ResultsPRNewsWire • 02/14/22
Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/22
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic HypersomniaPRNewsWire • 12/01/21
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/14/21
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/09/21
Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business UpdatesGlobeNewsWire • 11/09/21